Regen BioPharma Inc (RGBP)

[OTCShotCaller]

According to Barchart's trading history summary for RGBP:
https://www.barchart.com/stocks/quotes/RGBP/price-history/historical

1). RGBP's PPS INCREASED 2,445.5% From 2/1/21 To 4/23/21. Within this time period there were a total of 60 trading days. This translates into RGBP's PPS increasing by an average of 40.7 % per day amortized over this period.

When you look at this in perspective, it clearly points to a massive interest building in RGBP with a corresponding substantial rise in trading volume and PPS with expected pull backs due to high volatility, but nevertheless the overall trend is UPWARD! It is therefore logical that the massive interest in this stock will continue to rise with corresponding rises in the PPS.

Looking at the starting point when the Multi-Billion level breakout trading volume began on 4/8/21, i.e. 3,517,548,288 that represented a 571.43% increase in the PPS over the prior day, i,e, .0021 to .0141, there's no doubt where this is going long term.

The most recent High of 0.0593 hit on 4/12/21 on a Billion level break out volume of 1,896,574,976 nine trading days ago, in contrast to its 52-Week High of 0.08, it's just a matter of time before 0.08 is re-tested again, and surpassed due to the massive interest.

2). It's interesting to note that when a Google search is done on RGBP, Eli Lilly appears with mention of its partnership with RGBP for developing therapeutics to treat various cancers and autoimmune diseases AND that they reserve the right to "License or Buy RGBP's developed Compounds and/or New Drugs." (see 1st link below)

https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/5214863-regen-collaborative-agreement-eli-lilly-leads-to-success

https://www.prnewswire.com/news-releases/regen-biopharma-inc-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-and-company-585014641.html

https://www.hvst.com/posts/ongoing-agreement-with-eli-lilly-leads-to-discovery-of-several-new-small-molecule-drugs-wm4T1ZDp

https://www.proactiveinvestors.co.uk/companies/news/127723/regen-biopharma-inc-announced-drug-discovery-agreement-with-eli-lilly-and-company-127723.html

https://www.biospace.com/article/releases/regen-biopharma-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-/

https://www.sdbj.com/news/2016/jun/30/regen-biopharma-inks-deal-eli-lilly-and-co/


3). RGBP holds at least 23 Patents, at least one is presently in the discovery or pre-production phase with Eli Lilly and others with various CROs via RGBP's partnership with Oncology Pharma which is an Intellectual Property (IP) outsourcing pharmaceutical development Company. Just as a NOTE: it needs to be said that not ALL patents for pharmaceutical development make it to production, that should be obvious to most, BUT it only takes ONE (1) to generate BILLIONS in revenue, especially in the Hematology-Oncology Cancer treatment space.

https://patents.google.com/?inventor=David+Koos&sort=new


4). RGBP's Milestone Accomplishments History (includes Patents & Partnerships).

https://seekingalpha.com/symbol/RGBP/ratings/blogs

Keep in mind as previously stated RGBP is partnered with Oncology Pharma for development of its Patents that occurs through Contract Research Organization (CRO) outsourcing which is what Oncology Pharma does. This is how RGBP got partnered with Eli Lilly. Oncology Pharma outsources Intellectual Property Patents for pharmaceutical development and commercialization. Essentially, they're an IP Patent Broker exclusively in the pharmaceutical industry niche market of Hematology-Oncology.

Nothing is going to stop RGBP from moving UP into much higher trading PPS ranges but it's going to take time with Market recovery which is what Insider Financial mentions on the above link. ALL Markets turn around eventually.

Be well and prosper...